Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

• DOI: 10.2337/dc20-1521
• Publication Date: 2020-09-29T19:10:18Z
• Authors: Sebastiano Bruno ...; Francesca D’Addio; Roberto Trevisan; Elisabetta Lovati; Antonio Rossi; Ida Pastore; Marco Dell’Acqua; Elio Ippolito; Cristiana Scaranna; Rosalia Bellante; Silvia Galliani; Alessandro Robert...; Giuseppe Lepore; Francesca Geni; Roberta Maria Fio...; Emanuele Catena; Angelo Corsico; Riccardo Colombo; Marco Mirani; Carlo De Riva; Salvatore Endrio ...; Reza Abdi; Joseph V. Bonventre; Stefano Rusconi; Franco Folli; Antonio Di Sabatino; Gianvincenzo Zucc...; Massimo Galli; Paolo Fiorina
• Keywords: Coronaviru; Pneumonia, Viral; 610; Betacoronavirus; 03 medical and health sciences; 0302 clinical medicine; Retrospective Studie; Diabetes Mellitus; Humans; Viral; Pandemics; Retrospective Studies; Betacoronaviru; Pandemic; Emerging Therapies: Drugs and Regimens; Coronavirus Infection; SARS-CoV-2; Sitagliptin Phosphate; COVID-19; Pneumonia; 3. Good health; Coronavirus; Hospitalization; Diabetes Mellitus, Type 2; Italy; sitagliptin ; COVID-19; pneumonia; type 2 diabetes mellitus; inflammation; corona virus;; Coronavirus Infections; Type 2; Human

OBJECTIVE Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population. RESEARCH DESIGN AND METHODS In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral highly selective dipeptidyl peptidase 4 inhibitor, was added standard of care (e.g., insulin administration) at the time hospitalization who were hospitalized COVID-19. Every center also recruited 1:1 ratio untreated control subjects matched age sex. All had pneumonia exhibited oxygen saturation <95% when breathing ambient air or receiving support. The primary end points discharge from hospital/death improvement clinical outcomes, defined as increase least two on seven-category modified ordinal scale. Data collected retrospectively sitagliptin 1 March through 30 April 2020. RESULTS Of 338 consecutive COVID-19 admitted Northern Italy hospitals included 169 while care. Treatment associated reduced mortality (18% vs. 37% deceased patients; hazard 0.44 [95% CI 0.29–0.66]; P = 0.0001), (60% 38% improved 0.0001) greater number hospital discharges (120 89 discharged 0.0008) compared care, respectively. CONCLUSIONS study COVID-19, treatment standard-of-care treatment. effects should be confirmed ongoing randomized, placebo-controlled trial.